

**MINUTE
AREA DRUG AND THERAPEUTICS COMMITTEE
WEDNESDAY 16^h FEB @10am
Microsoft Teams Meeting**

In Attendance:

Dr Mehrdad Malekian	Mrs Karen Patterson	Mrs Christine Gilmour
Dr Tyra Smyth	Mrs Emma Harris	Dr David Semple
Mrs Penny Brankin	Mrs Carol McGoff	Mr John Milne
Mrs Katrina Maroni	Mrs Gail Richardson	Mr George Lindsay
Dr Iain Hathorn	Ms Ann Auld	

		Action
2022/19	<p>1. <u>Apologies for Absence</u> Mr Bill Angus. Mrs Linda Johnstone, Dr Stephanie Dundas</p>	
2022/20	<p>2. <u>Declaration of Interest</u> There were no declarations of interest.</p>	
2022/21	<p>3. <u>Matters arising not covered elsewhere on the agenda</u></p> <p>a. <u>Ratification of minutes of meeting 19th January 2022</u> The minute was accepted as an accurate record.</p> <p>b. <u>Oxygen Prescribing in Acute Settings</u> This is ongoing. Dr Smyth asked that interface issues for patients being discharged on oxygen be included in the discussions.</p> <p>c. <u>Steroid Emergency Cards</u> This item is ongoing. Mr Lindsay reported on discussions at the ADTCC Forum on 9th Feb regarding the possibility of utilising the STU tool to aid identification of patients but that this would not be a quick solution. Balancing the risks and benefits of different targeting tools to get this information to the patients who may benefit needs to be considered as does the interface between the new steroid emergency cards and the traditional blue cards.</p>	<p>MM</p> <p>CG</p>

d.	<p><u>Ravulizumab</u></p> <p>This was approved and Mr Milne will feedback to the authors.</p>	JM
2022/22 4.	<p><u>SMC ADVICE</u></p> <p><u>FULL SUBMISSIONS</u></p> <p>Solriamfetol (Sunosi®) SMC2419 This was noted.</p> <p>Sacituzumab govitecan (Trodelvy®) SMC2446 This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p>Sotorasib (Lumykras®) SMC2443 This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p>Hydrocortisone (Efmody®) SMC2414 This was noted.</p> <p>Berotrastat (Orladeyo®) SMC2405 This was noted and will be referred to immunology specialists.</p> <p><u>NON SUBMISSIONS</u></p> <p>Blinatumomab (Blincyto®) SMC2468 This was noted.</p> <p>Daratumumab (Darzalex®) SMC2469 This was noted.</p> <p>Givosiran (Givlaari®) SMC2470 This was noted.</p> <p>Betula verrucosa (Itulazax®) SMC2471 This was noted.</p> <p><u>DEFERRED ADVICE</u></p> <p>Dostarlimab (Jemperli®) SMC2404 This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p><u>AMENDED ADVICE</u></p> <p>Cenobamate (Ontozry®) SMC2408 This was noted.</p> <p>Cannabidiol (Epidyolex®) SMC2402 This was noted.</p>	

	<p>Risdiplam (Evrysdi®) SMC2401 This was noted.</p> <p>UPDATE ON THE INTERIM ASSESSMENT APPROACH IN RESPONSE TO COVID-19 This is a pragmatic approach to minimise delay in patient access as a result of the COVID-19 pandemic. Following review by the SMC executive, SMC advice for one submission noted below will be published on the SMC website on Monday 07 March 2022.</p> <p>ABBREVIATED SUBMISSION</p> <p>Lorlatinib (Lorviqua®) SMC2415 This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p>	
2022/23 5.	<p><u>SMC follow up</u></p> <p>Mrs Maroni talked the committee through the SMC follow up which had been previously circulated. Feedback on a number of items is pending. Dr Malekian and Mrs Maroni will meet to discuss next steps.</p>	
2022/24 6.	<p><u>Lanarkshire Formulary</u></p> <p>There were no formulary amendments for this month.</p> <p>Mrs Maroni gave an overview of the formulary website migration, including the impact of software updates and the projected timeline for launch. The introduction section will outline aspects of the editorial functionality and will include a generic inbox to submit comments.</p>	
2022/25 7.	<p><u>Clinical Protocols</u></p> <p>a. <u>Ivacaftor 37.5mg/Tezacaftor 25mg/Elexacaftor 50mg (Kaftrio®)</u></p> <p>This was approved and it was noted that the advice given within the MHRA warning of Feb 22 was incorporated. Mrs Richardson will feedback to the authors.</p> <p>b. <u>Management of Cholesterol in Adults</u></p> <p>There was a full discussion which welcomed this comprehensive guideline. Feedback will go to Mrs Milne to consider:</p> <ul style="list-style-type: none"> • reviewing typographical errors, including mmmol • clarifying how GPs may refer patients to the lipid clinic • recent SMC advice regarding bempedoic acid/ezetimibe (Nustendi®) 	GR
2022/26 8.	<p><u>ADTC New Medicines Decisions</u></p> <p>This was noted.</p>	KM

2022/27 9.	<p><u>Unlicensed Medicines</u></p> <p>Mrs Gilmour discussed the clinical use of Paxlovid and Sotrovimab for up to 7 days since the onset of symptoms. This is in line with the UK Clinical Commissioning policy. It was also explained that the Community Covid Pathway has been given "Bronze" status and it was agreed that the Chair of that group is most appropriate for authorising this use outwith licence.</p>	CG
2022/28 10.	<p><u>Patient Group Directions</u></p> <p>Mr Lindsay explained the context for the Patient Group Directions for Sexual Health. Committee members requested further time to review the detail and feedback by end Feb with a view that revised drafts be brought to the meeting on 16th March. Mr Lindsay will liaise with Dr McLellan about this and arrangements post her retiral.</p>	GL
2022/29 11.	<p><u>Medication and Clinical risk in Lanarkshire</u></p> <p>There was nil to note at today's meeting.</p>	
2022/30 12.	<p><u>Regional Cancer Advisory Network</u></p> <p>Mr Milne gave an overview of the individual protocols as well as the governance structures in which they are developed and approved.</p>	
2022/31 13.	<p><u>Patient Safety Alerts</u></p> <p>There was nil to report at this today's meeting.</p>	
2022/32 14.	<p><u>Lay member related items</u></p> <p>There was nil to report at this today's meeting.</p>	
2022/33 15.	<p><u>Correspondence</u></p> <p><u>ADTCC FORUM</u></p> <p>Mr Lindsay reported back on the key points from last week's ADTCC Forum.</p>	
2022/34 16	<p><u>Pharmacy & NMAHP Prescribing Governance</u></p> <p>The plans for updating systems for PGD approval were noted.</p>	
2022/35 17.	<p><u>AOCB</u></p> <p>a. <u>Private prescriptions</u></p> <p>There was a wide ranging discussion which identified that the challenges associated with this topic were becoming more pressing because of the</p>	

	<p>effects of the pandemic and a greater number of patients seeking private healthcare.</p> <p>It was recognised that the issues go beyond recommendations back to the GP for medication and a set of principles governing the whole issue would be valuable. The ADTC would contribute to but not lead this work.</p> <p>b. <u>SGLT2 Alert</u></p> <p>Mrs Patterson described plans by Dr Mukhopadhyay to distribute safety guidance to patients receiving SGLT2 medication.</p> <p>It was agreed that a working group consisting of representatives from hospital medical and pharmacy staff, General Practitioners, General Practice Clinical Pharmacists and Community Pharmacy could review the proposals to clarify the outcomes required and prepare a plan. There may be a place to use the STU tool to identify patients receiving these medicines.</p> <p>c. <u>Heparin Chart</u></p> <p>Mrs Patterson discussed a change planned for the Heparin Chart which currently describes a target APTT range of 1.8-2.8. This is different from the lab reports which reference a range of 1.5-2.5. With agreement of Dr Hung it has been agreed to change the chart to make it consistent with the lab system.</p> <p>d. <u>Peri-Procedure management of Anticoagulation.</u></p> <p>Mrs Richardson indicated that a guideline on this topic was being prepared for the ADTC to review.</p>	<p>KP</p> <p>KP</p>
<p>2022/36 18.</p>	<p><u>Date of next meeting</u></p> <p>Wednesday 16th March 2022 10am @ Microsoft Teams</p>	